Artiva Biotherapeutics (ARTV) Net Income towards Common Stockholders: 2023-2024
Historic Net Income towards Common Stockholders for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$16.1 million.
- Artiva Biotherapeutics' Net Income towards Common Stockholders fell 41.30% to -$16.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$61.9 million, marking a year-over-year change of. This contributed to the annual value of -$65.4 million for FY2024, which is 127.62% down from last year.
- Artiva Biotherapeutics' Net Income towards Common Stockholders amounted to -$16.1 million in Q4 2024, which was up 2.42% from -$16.5 million recorded in Q3 2024.
- In the past 5 years, Artiva Biotherapeutics' Net Income towards Common Stockholders registered a high of $11.2 million during Q3 2023, and its lowest value of -$16.7 million during Q2 2023.
- Moreover, its 2-year median value for Net Income towards Common Stockholders was -$15.5 million (2024), whereas its average is -$11.3 million.
- Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Net Income towards Common Stockholders showed a top increase of 6.90% in 2024 and a maximum decrease of 246.84% in 2024.
- Artiva Biotherapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$11.4 million in 2023, then tumbled by 41.30% to -$16.1 million in 2024.
- Its Net Income towards Common Stockholders was -$16.1 million in Q4 2024, compared to -$16.5 million in Q3 2024 and -$15.5 million in Q2 2024.